The $68 billion acquisition will solidify Pfizer’s standing as the top-selling drugmaker. Bottles of Pfizer’s Lipitor, left, and Wyeth’s Effexor are shown. Shareholders of Wyeth voted overwhelmingly ...

Could a patent infringement case filed against Pfizer just before the holiday help Elan CEO Kelly Martin in his negotiations with Wyeth over revenues from bapineuzamab, his Alzheimer's drug? The ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

) named Mikael Dolsten, M.D., PhD, President of Pfizer Worldwide Research and Development, as the Company completes its integration of these functions following the Wyeth acquisition. Dr. Dolsten ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read my latest analysis of PFE stock.